Pharmafile Logo
Pharmafocus logo
Advanced Search

crizotinib

Showing 13 posts of 13 posts found.

Novartis’ Zykadia more effective than chemo, new study shows

October 13, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alcensa, Novartis, Roche, Xalkori, ceritinib, crizotinib, lung cancer, zykadia

Phase III results for Novartis’ cancer drug Zykadia (ceritinib) have revealed it as more effective than chemo at halting progression …

News
roche_side_building

Roche’s Alecensa receives second FDA Breakthrough Therapy Designation

October 4, 2016
Manufacturing and Production ALK+, Alecensa, FDA, Roche, alk, crizotinib

Alecensa has been designated as a breakthrough therapy, which will speed up the process towards FDA approval, should clinical trials …

News

Pfizer’s Xalkori price drop secures NICE recommendation

August 18, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, Pfizer, Xalkori, crizotinib, lung cancer

The National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Xalkori (crizotinib) as a treatment for lung cancer, …

News
Xalkori

Pfizer lung cancer treatment gets expanded EU approval

December 1, 2015
Research and Development, Sales and Marketing NSCLC, Pfizer, Xalkori, crizotinib, lung cancer, non-small cell lung cancer

Pfizer UK has received European Commission approval for a label update to expand use of Xalkori (crizotinib) to first-line treatment …

News

FDA approves Pfizer’s lung cancer drug Xalkori

August 30, 2011
Sales and Marketing FDA, Pfizer, Xalkori, crizotinib

Pfizer’s lung cancer drug Xalkori has been approved by the FDA, a month ahead of schedule. Xalkori (crizotinib) is now …

News
Pfizer

EMA to review two new Pfizer cancer drugs

August 19, 2011
Sales and Marketing Cancer, Pfizer, bosutinib, crizotinib

The EMA has accepted Pfizer’s regulatory submissions for two of its new cancer compounds. The first is its much-lauded crizotinib, …

News

Pfizer files lung cancer drug in US and Japan

May 18, 2011
Sales and Marketing NSCLC, Pfizer, crizotinib

Pfizer has submitted its oral lung cancer drug crizotinib for regulatory approval in the US and Japan. Crizotinib is an …

News
Lung cancer cells

No magic bullet, but a growing arsenal against lung cancer

February 23, 2011
Research and Development ASA404, Cancer, Iressa, NSCLC, Tarceva, afatinib, crizotinib, figitumumab, lung cancer, non small cell lung cancer, non-small cell lung cancer

A man in his 70s is waiting for his appointment with the oncologist after being referred there by his family …

Feature
AstraZeneca's Iressa (gefitinib)

AZ and Pfizer support personalised medicine database

February 8, 2011
Research and Development AZ, AstraZeneca, Cancer Research UK, Iressa, Pfizer, crizotinib, gefitinib, personalised medicine

AstraZeneca and Pfizer have teamed up with leading charity Cancer Research UK to help develop its stratified medicines programme. Stratified …

News

Key drug launches for 2011

January 20, 2011
Sales and Marketing Benlysta, Cladribine, Movectro, Pradaxa, Xarelto, axitinib, boceprevir, crizotinib, telaprevir

This year is expected to see new treatments for hepatitis C, multiple sclerosis and lupus among those that could reach …

Feature
Pfizer's Lipitor tablet

Pfizer lung cancer drug gets ‘rolling’ fast-track status in US

January 13, 2011
Sales and Marketing Cancer, NSCLC, axitinib, bosutinib, crizotinib, non-small cell lung cancer

Pfizer has initiated a ‘rolling’ submission for its new oral ALK lung cancer drug crizotinib that could see it on …

News

Pfizer to seek US approval for crizotinib next year

November 1, 2010
Research and Development, Sales and Marketing FDA submission, NSCLC, Pfizer, crizotinib, lung cancer, non-small cell lung cancer

Pfizer will submit its lung cancer candidate crizotinib to the FDA for US approval in the first half of next …

News

‘Stellar’ performance from targeted lung cancer drug

June 9, 2010
Research and Development Pfizer, biomarkers, crizotinib

A new targeted treatment for non small cell lung cancer has produced spectacular results in a sub-group of patients. Pfizer’s …

News

Latest content

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024

Veru announces first patients enrolled in phase 2b trial for weight loss treatment

May 1, 2024

Bayer and Evotec to collaborate on precision cardiology

April 30, 2024

PeptiDream and Novartis extend peptide discovery collaboration

April 30, 2024

Pfizer’s Beqvez approved by FDA for haemophilia B treatment

April 29, 2024